ASH News Daily 2017 - Issue 2 - A-20

Page A-20

ASH NEWS DAILY

Sunday, December 10, 2017

VTE

«« From Page A-12

Speakers and attendees interact during the Grassroots Network Lunch,
which featured a talk from NBCUniversal executive Alan Wurtzel.

She said there remains a need to
better define high-risk patients to
allow for a more individualized
approach.
Dr. Pabinger concluded that the
present guidelines, which recommend LMWH for the treatment
of cancer-associated VTE, will be
outdated as of Tuesday, December
12, when Dr. Gary Raskob of the
University of Oklahoma College of
Public Health presents late-breaking abstract 6, "A Randomized,
Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxa-

YOUR SOURCE FOR WORLDWIDE NEWS AND
PERSPECTIVES IN HEMATOLOGY/ONCOLOGY

ASH Clinical News, an award-winning publication from the
American Society of Hematology, features:
✓ Insightful editorials and in-depth feature articles
✓ Coverage of practice-changing research
✓ Interviews with innovators and mentors in hematology
✓ Challenging clinical cases - answered by experts
(and our readers!)
Pick up a copy in one of the bins located throughout
the convention center.
ashclinicalnews.org | @ASHClinicalNews

Anticoagulant therapy can
be continued for high-risk
factors including metastatic
or progressive disease, chemotherapy, or thrombogenic
therapy, and discontinued if
there is active or recurrent
serious bleeding, cancer in
remission, or a tumor type at
low risk for recurrent VTE.
ban Versus Dalteparin for Venous
Thromboembolism
Associated
with Cancer: Hokusai VTE-Cancer
Study" during the LBA session
from 7:30 to 9:00 a.m. in Hall C2C3 of the Georgia World Congress
Center. The study concludes that
oral edoxaban for up to 12 months
is noninferior to subcutaneous
dalteparin for the treatment of cancer-associated VTE. Dr. Pabinger
recommends DOACs for those patients who do not tolerate LMWH
injections. She noted that there are
drug interactions between DOACs
and cancer therapeutics, and "we
don't know enough about the clinical relevance of these drug interactions."
ASH's development of clinical guidelines began in earnest in
2015 with the meetings of 10 panels on VTE guidelines. The first set
of these guidelines were presented
Saturday at a special education
session. Co-chair Dr. Adam Cuker
from the University of Pennsylvania said he expected the first four
to six ASH VTE guidelines will
be published in 2018. Co-chair Dr.
Holger Schünemann of McMaster
University highlighted methods
that were used to develop the VTE
guidelines.
Representatives from each of
the 10 VTE panels highlighted one
key recommendation from their respective panels. For example, Dr.
Gary Lyman with Fred Hutchinson Cancer Research Center, and
chair of the cancer-associated VTE
panel, said the panel conditionally
recommends LMWH for high-risk
ambulatory patients with no major
bleeding risks who are receiving
chemotherapy, but found that more
data on risk factors are needed.
There is also an education session, "Controversies in Venous
Thromboembolism: To Treat or
Not to Treat," offered today at 9:30
a.m. and tomorrow at 2:45 p.m. in
Room B308-B309 and B304-B305,
respectively, in the Georgia World
Congress Center.
If you missed today's 7:30 a.m.
or 9:30 a.m. sessions due to the
weather, they will be recorded and
made available to all registered attendees.
Dr. Lederman indicated no relevant
conflicts of interest.

http://www.ashclinicalnews.org

Table of Contents for the Digital Edition of ASH News Daily 2017 - Issue 2